| # | Side effect | Count |
|---|---|---|
| 0 | NO ADVERSE EVENT | 378 |
| 1 | PRODUCT AVAILABILITY ISSUE | 236 |
| 2 | BLADDER CANCER RECURRENT | 187 |
| 3 | PRODUCT DOSE OMISSION | 177 |
| 4 | PRODUCT DOSE OMISSION ISSUE | 107 |
| 5 | DRUG INEFFECTIVE | 88 |
| 6 | PYREXIA | 83 |
| 7 | DISSEMINATED BACILLUS CALMETTE-GUERIN INFECTION | 72 |
| 8 | THERAPY NON-RESPONDER | 72 |
| 9 | PRODUCT SUPPLY ISSUE | 67 |
| # | Side effect | Count | Frequency |
|---|---|---|---|
| 0 | CANCER CELLS URINE PRESENT | 3 | 0.5000 |
| 1 | HIGH INTENSITY FOCUSED ULTRASOUND | 1 | 0.3333 |
| 2 | BLADDER GRANULOMA | 4 | 0.3333 |
| 3 | BCG RELATED CYSTITIS | 6 | 0.3000 |
| 4 | BLADDER CANCER RECURRENT | 187 | 0.1876 |
| 5 | RADICAL CYSTECTOMY | 6 | 0.1714 |
| 6 | MANUFACTURING STABILITY TESTING ISSUE | 1 | 0.1667 |
| 7 | DISSEMINATED BACILLUS CALMETTE-GUERIN INFECTION | 72 | 0.1542 |
| 8 | CYSTITIS EROSIVE | 1 | 0.1429 |
| 9 | KOEPPE NODULES | 1 | 0.1250 |